172 related articles for article (PubMed ID: 37429785)
1. Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma.
Shi ZX; Li CF; Zhao LF; Sun ZQ; Cui LM; Xin YJ; Wang DQ; Kang TR; Jiang HJ
Hepatobiliary Pancreat Dis Int; 2024 Aug; 23(4):361-369. PubMed ID: 37429785
[TBL] [Abstract][Full Text] [Related]
2. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
Niu XK; He XF
World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
[TBL] [Abstract][Full Text] [Related]
3. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE.
Kong C; Zhao Z; Chen W; Lv X; Shu G; Ye M; Song J; Ying X; Weng Q; Weng W; Fang S; Chen M; Tu J; Ji J
Eur Radiol; 2021 Oct; 31(10):7500-7511. PubMed ID: 33860832
[TBL] [Abstract][Full Text] [Related]
4. Contrast-Enhanced CT Imaging Features Combined with Clinical Factors to Predict the Efficacy and Prognosis for Transarterial Chemoembolization of Hepatocellular Carcinoma.
Sun Z; Shi Z; Xin Y; Zhao S; Jiang H; Li J; Li J; Jiang H
Acad Radiol; 2023 Sep; 30 Suppl 1():S81-S91. PubMed ID: 36803649
[TBL] [Abstract][Full Text] [Related]
5. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
6. Predicting Survival Using Pretreatment CT for Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Comparison of Models Using Radiomics.
Kim J; Choi SJ; Lee SH; Lee HY; Park H
AJR Am J Roentgenol; 2018 Nov; 211(5):1026-1034. PubMed ID: 30240304
[TBL] [Abstract][Full Text] [Related]
7. Preoperative CECT-based Radiomic Signature for Predicting the Response of Transarterial Chemoembolization (TACE) Therapy in Hepatocellular Carcinoma.
Bai H; Meng S; Xiong C; Liu Z; Shi W; Ren Q; Xia W; Zhao X; Jian J; Song Y; Ni C; Gao X; Li Z
Cardiovasc Intervent Radiol; 2022 Oct; 45(10):1524-1533. PubMed ID: 35896687
[TBL] [Abstract][Full Text] [Related]
8. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion.
Sheen H; Kim JS; Lee JK; Choi SY; Baek SY; Kim JY
Abdom Radiol (NY); 2021 Jun; 46(6):2839-2849. PubMed ID: 33388805
[TBL] [Abstract][Full Text] [Related]
9. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
11. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
[TBL] [Abstract][Full Text] [Related]
12. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma.
Li L; Kan X; Zhao Y; Liang B; Ye T; Yang L; Zheng C
Int J Med Sci; 2021; 18(11):2276-2284. PubMed ID: 33967603
[No Abstract] [Full Text] [Related]
13. Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study.
Wang DD; Zhang JF; Zhang LH; Niu M; Jiang HJ; Jia FC; Feng ST
Hepatobiliary Pancreat Dis Int; 2023 Dec; 22(6):594-604. PubMed ID: 36456428
[TBL] [Abstract][Full Text] [Related]
14. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
15. Computed tomography texture analysis combined with preoperative clinical factors serve as a predictor of early efficacy of transcatheter arterial chemoembolization in hepatocellular carcinoma.
Fan XL; Wang YH; Chen YH; Chen BX; Cai JN; Yang JS; Sun X; Yan FR; He BS
Abdom Radiol (NY); 2023 Jun; 48(6):2008-2018. PubMed ID: 36943423
[TBL] [Abstract][Full Text] [Related]
16. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
[TBL] [Abstract][Full Text] [Related]
17. Selection Between Liver Resection Versus Transarterial Chemoembolization in Hepatocellular Carcinoma: A Multicenter Study.
Fu S; Wei J; Zhang J; Dong D; Song J; Li Y; Duan C; Zhang S; Li X; Gu D; Chen X; Hao X; He X; Yan J; Liu Z; Tian J; Lu L
Clin Transl Gastroenterol; 2019 Aug; 10(8):e00070. PubMed ID: 31373932
[TBL] [Abstract][Full Text] [Related]
18. CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus.
Cheng S; Hu G; Jin Z; Wang Z; Xue H
Eur Radiol; 2023 Dec; 33(12):8715-8726. PubMed ID: 37436507
[TBL] [Abstract][Full Text] [Related]
19. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF
J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
[TBL] [Abstract][Full Text] [Related]
20. Non-invasive assessment of response to transcatheter arterial chemoembolization for hepatocellular carcinoma with the deep neural networks-based radiomics nomogram.
Liu Y; Liu Z; Li X; Zhou W; Lin L; Chen X
Acta Radiol; 2024 Jun; 65(6):535-545. PubMed ID: 38489805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
